Suppr超能文献

健康经济证据在结直肠癌临床实践指南中的作用:一项跨国比较分析。

The role of health economic evidence in clinical practice guidelines for colorectal cancer: a comparative analysis across countries.

作者信息

Yan Xiaoyu, Wang Yue, Ma Aixia, Li Hongchao

机构信息

School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, People's Republic of China.

School of International Pharmaceutical Business & Center for Pharmacoeconomics & Outcomes Research, China Pharmaceutical University, Nanjing, Jiangsu, People's Republic of China.

出版信息

J Comp Eff Res. 2025 Apr;14(4):e240226. doi: 10.57264/cer-2024-0226. Epub 2025 Feb 19.

Abstract

Colorectal cancer (CRC) is among the most prevalent malignancies globally and causes massive resource consumption and economic burden. Health economic evidence (HEE) has been used in clinical practice guidelines (CPGs) for cancer to facilitate the rational allocation of health resources. However, in certain guideline development organizations, HEE is not yet utilized as a formal decision-making criterion. This study aimed to compare the discrepancies in the utilization of health economics as evidence in CRC CPGs across different countries and review specific features of economic evidence concerning the guidelines' applicability. A systematic review was conducted using databases including Medline, Embase, CNKI, WanFang, and other guidelines databases to identify CPGs for CRC published in English or Chinese from January 2017 to September 2023. Data on the incorporation and application of HEE were extracted, and the method and quality of cost-effectiveness analysis (CEA) studies were evaluated. Descriptive analyses were used to summarize the results. Out of 53 CPGs from 14 countries, most originated from the USA (n = 17 of 53 [32%]) and Canada (n = 9 of 53 [17%]). Sixty-eight percent (36/53) considered cost justification, and 57% (30/53) incorporated health economics studies as evidence. The included HEE cited in CPGs ranged from 1990 to 2021 and were not aligned with the countries in which the guidelines were issued. Among these CEA studies, 52% (26/50) were related to screening strategies, and 32% (16/50) pertained to treatment measures. The Markov model was the most frequently used (n = 27 of 50 [54%]). Based on the CHEQUE tool, the methodological quality of these CEA studies was inadequate in areas such as multiple data sources, approaches to select data sources, assessing the quality of data, and relevant equity or distribution. In summary, 57% of guidelines incorporated health economics studies as evidence, with a variation between different countries. The included HEE still had deficiencies in methodology and reporting quality. In the future, it is suggested that health economics research should use a standardized methodology and reporting approach to assist in clinical decision making.

摘要

结直肠癌(CRC)是全球最常见的恶性肿瘤之一,会导致大量资源消耗和经济负担。卫生经济证据(HEE)已被用于癌症临床实践指南(CPG)中,以促进卫生资源的合理分配。然而,在某些指南制定组织中,HEE尚未被用作正式的决策标准。本研究旨在比较不同国家在CRC CPG中作为证据使用卫生经济学的差异,并回顾经济证据在指南适用性方面的具体特征。使用包括Medline、Embase、CNKI、万方和其他指南数据库在内的数据库进行系统评价,以识别2017年1月至2023年9月以英文或中文发表的CRC CPG。提取关于HEE纳入和应用的数据,并评估成本效益分析(CEA)研究的方法和质量。采用描述性分析总结结果。在来自14个国家的53项CPG中,大多数来自美国(53项中的17项[32%])和加拿大(53项中的9项[17%])。68%(36/53)考虑了成本合理性,57%(30/53)将卫生经济学研究作为证据纳入。CPG中纳入的HEE发表时间从1990年到2021年不等,且与指南发布国家不一致。在这些CEA研究中,52%(26/50)与筛查策略相关,32%(16/50)与治疗措施相关。马尔可夫模型是最常用的(50项中的27项[54%])。基于CHEQUE工具,这些CEA研究在多个数据源、选择数据源的方法、评估数据质量以及相关公平性或分配等方面的方法学质量不足。总之,57%的指南将卫生经济学研究作为证据纳入,不同国家之间存在差异。纳入的HEE在方法学和报告质量方面仍存在不足。未来,建议卫生经济学研究应采用标准化的方法和报告方法来协助临床决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef68/11963387/53af6e7434c7/cer-14-240226-g1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验